<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708524</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5808</org_study_id>
    <nct_id>NCT02708524</nct_id>
  </id_info>
  <brief_title>Clinical Study of Approved and Investigational Contact Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, 5-visit, double-masked, dispensing study comparing an investigational
      contact lens with currently-marketed contact lenses. The objective of the study is to
      evaluate the comfort of the lenses when worn for 30 (-2/+6) days on daily wear modality.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Overall Comfort Composite Score</measure>
    <time_frame>Up to 1 month Follow-up</time_frame>
    <description>Subjective Overall Comfort was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.Range is 0 to 120. CLUE was collect at Baseline, Post Lens Fit 1-, 2-, 3- and 4- week follow-ups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Comfort Individual Item</measure>
    <time_frame>1 month follow-up</time_frame>
    <description>Overall Comfort was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Responses are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort at the End of the Day Individual Item</measure>
    <time_frame>1 month Follow-up</time_frame>
    <description>Comfort at the End of the Day was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 like-rt scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort Each and Everyday Individual Item</measure>
    <time_frame>1 month Follow-up</time_frame>
    <description>Comfort each and everyday was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Lens Awareness Individual Item</measure>
    <time_frame>1 month Follow-up</time_frame>
    <description>Frequency of Lens Awareness was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are scaled as (Always, Frequently, Occasionally, Rarely, Never or Don't Know). Only the number of participants that reported Rarely or Never (Top-Two-Box) was reported here.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Experiencing Dryness Individual Item</measure>
    <time_frame>1 month Follow-up</time_frame>
    <description>Frequency of Experiencing Dryness was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are scaled as (Always, Frequently, Occasionally, Rarely, Never or Don't Know). Only the number of participants that reported Rarely or Never (Top-Two-Box) was reported here.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Making Your Eyes Feel Moist Throughout the Day Individual Item</measure>
    <time_frame>Up to 1 month Follow-up</time_frame>
    <description>Making your eyes feel moist throughout the day was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Overall Quality of Vision Composite Score</measure>
    <time_frame>Up to 1 month Follow-up</time_frame>
    <description>Subjective Overall Quality of Vision was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. CLUE was collect at Baseline, Post Lens Fit 1-, 2-, 3- and 4- week follow-ups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of Vision Individual Item</measure>
    <time_frame>Up to 1 month Follow-up</time_frame>
    <description>Overall Quality of Vision was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the number of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Opinion Individual Item</measure>
    <time_frame>Up to 1 month Follow-up</time_frame>
    <description>Overall Opinion was assessed using a questionnaire item at Post Fit, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">554</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Senofilcon C Wearers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comfilcon A Wearers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrafilcon B Wearers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Samfilcon A Wearers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon C Contact Lens</intervention_name>
    <arm_group_label>Senofilcon C Wearers</arm_group_label>
    <other_name>senofilcon C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comfilcon A Contact Lens</intervention_name>
    <arm_group_label>Comfilcon A Wearers</arm_group_label>
    <other_name>comfilcon A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B Contact Lens</intervention_name>
    <arm_group_label>Lotrafilcon B Wearers</arm_group_label>
    <other_name>lotrafilcon B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Samfilcon A Contact Lens</intervention_name>
    <arm_group_label>Samfilcon A Wearers</arm_group_label>
    <other_name>samfilcon A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
             receive a fully executed copy of the form.

          2. The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol.

          3. The subject must be between 18 to 40 years of age at the time of consent.

          4. The subject's spherical equivalent distance refraction must be in the range of -1.25
             to -6.00 in each eye.

          5. The subject's refractive cylinder must be ≤1.00D in each eye.

          6. The subject must have best corrected visual acuity of 20/30 or better in each eye.

          7. The subject must be a habitual frequent replacement (reusable) daily wear spherical
             silicone hydrogel soft contact lens wearer in both eyes.

          8. The subject must be able to wear contact lenses for a minimum of 8 hours, 4 days per
             week.

          9. The subject must have normal eyes (i.e., no ocular medications or infections of any
             type).

        Exclusion Criteria:

          1. Currently pregnant or lactating (subjects who become pregnant during the study will be
             discontinued).

          2. Any ocular or systemic allergies or diseases that may interfere with contact lens
             wear.

          3. Any systemic disease, autoimmune disease, or use of medication, which may interfere
             with contact lens wear.

          4. Any known sensitive/allergic to Ingredients of OPTI-FREE® PureMoist® solution.

          5. Any daily disposable, extended wear, monovision, toric or multi-focal contact lens
             correction.

          6. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of
             recurrent corneal erosions, aphakia, or moderate or above corneal distortion.

          7. Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy,
             photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK),
             etc.)

          8. Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization,
             corneal staining, tarsal abnormalities, conjunctival injection) on the FDA
             classification scale, any previous history or signs of a contact lens-related corneal
             inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any
             other ocular abnormality that may contraindicate contact lens wear.

          9. Any ocular infection.

         10. Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

         11. Participation in any contact lens or lens care product clinical trial within 7 days
             prior to study enrollment.

         12. History of binocular vision abnormality or strabismus.

         13. Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious
             immunosuppressive disease (e.g., HIV), by self-report).

         14. Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fruit Cove</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Closter</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <results_first_submitted>August 3, 2016</results_first_submitted>
  <results_first_submitted_qc>September 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2016</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 554 subjects were enrolled in this study. Of the enrolled subjects 6 subjects did not meet the eligibility criteria and 548 subjects were dispensed a study lens. Of the dispensed subjects 535 subjects completed the study and 13 subjects were discontinued.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon C</title>
          <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
        </group>
        <group group_id="P2">
          <title>Comfilcon A</title>
          <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
        </group>
        <group group_id="P3">
          <title>Lotrafilcon B</title>
          <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
        </group>
        <group group_id="P4">
          <title>Samfilcon A</title>
          <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lens Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dispensed incorrect study lens</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not wear lens at final visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject lost study lens</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that were dispensed a study lens.</population>
      <group_list>
        <group group_id="B1">
          <title>Senofilcon C</title>
          <description>All subjects that wore the senofilcon C lens throughout the duration of the study.</description>
        </group>
        <group group_id="B2">
          <title>Comfilcon A</title>
          <description>All subjects that wore the comfilcon A lens throughout the duration of the study.</description>
        </group>
        <group group_id="B3">
          <title>Lotrafilcon B</title>
          <description>All subjects that wore the lotrafilcon B lens throughout the duration of the study.</description>
        </group>
        <group group_id="B4">
          <title>Samfilcon A</title>
          <description>All subjects that wore the samfilcon A lens throughout the duration of the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="137"/>
            <count group_id="B4" value="136"/>
            <count group_id="B5" value="548"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="6.24"/>
                    <measurement group_id="B2" value="27.7" spread="5.86"/>
                    <measurement group_id="B3" value="28.6" spread="5.63"/>
                    <measurement group_id="B4" value="28.8" spread="6.56"/>
                    <measurement group_id="B5" value="28.6" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Overall Comfort Composite Score</title>
        <description>Subjective Overall Comfort was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.Range is 0 to 120. CLUE was collect at Baseline, Post Lens Fit 1-, 2-, 3- and 4- week follow-ups.</description>
        <time_frame>Up to 1 month Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Overall Comfort Composite Score</title>
          <description>Subjective Overall Comfort was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.Range is 0 to 120. CLUE was collect at Baseline, Post Lens Fit 1-, 2-, 3- and 4- week follow-ups.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>average clue score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.17" spread="23.612"/>
                    <measurement group_id="O2" value="68.58" spread="21.993"/>
                    <measurement group_id="O3" value="66.45" spread="22.864"/>
                    <measurement group_id="O4" value="65.46" spread="22.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Fit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.65" spread="16.198"/>
                    <measurement group_id="O2" value="62.11" spread="18.814"/>
                    <measurement group_id="O3" value="52.27" spread="22.762"/>
                    <measurement group_id="O4" value="64.40" spread="19.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.29" spread="22.863"/>
                    <measurement group_id="O2" value="55.78" spread="26.628"/>
                    <measurement group_id="O3" value="54.40" spread="26.260"/>
                    <measurement group_id="O4" value="56.96" spread="25.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.18" spread="22.455"/>
                    <measurement group_id="O2" value="55.56" spread="24.955"/>
                    <measurement group_id="O3" value="53.09" spread="26.908"/>
                    <measurement group_id="O4" value="55.01" spread="24.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.31" spread="23.850"/>
                    <measurement group_id="O2" value="55.01" spread="27.069"/>
                    <measurement group_id="O3" value="52.17" spread="26.585"/>
                    <measurement group_id="O4" value="53.72" spread="26.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.74" spread="26.121"/>
                    <measurement group_id="O2" value="56.32" spread="27.549"/>
                    <measurement group_id="O3" value="51.15" spread="28.609"/>
                    <measurement group_id="O4" value="52.61" spread="27.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort Individual Item</title>
        <description>Overall Comfort was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Responses are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
        <time_frame>1 month follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort Individual Item</title>
          <description>Overall Comfort was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Responses are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                    <measurement group_id="O2" value="50.7"/>
                    <measurement group_id="O3" value="51.9"/>
                    <measurement group_id="O4" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9"/>
                    <measurement group_id="O2" value="54.7"/>
                    <measurement group_id="O3" value="48.2"/>
                    <measurement group_id="O4" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="45.2"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comfort at the End of the Day Individual Item</title>
        <description>Comfort at the End of the Day was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 like-rt scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
        <time_frame>1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort at the End of the Day Individual Item</title>
          <description>Comfort at the End of the Day was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 like-rt scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5"/>
                    <measurement group_id="O2" value="64.6"/>
                    <measurement group_id="O3" value="60.9"/>
                    <measurement group_id="O4" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="47.0"/>
                    <measurement group_id="O3" value="43.6"/>
                    <measurement group_id="O4" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="42.3"/>
                    <measurement group_id="O3" value="42.1"/>
                    <measurement group_id="O4" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="39.8"/>
                    <measurement group_id="O4" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comfort Each and Everyday Individual Item</title>
        <description>Comfort each and everyday was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
        <time_frame>1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort Each and Everyday Individual Item</title>
          <description>Comfort each and everyday was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="76.1"/>
                    <measurement group_id="O3" value="78.3"/>
                    <measurement group_id="O4" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                    <measurement group_id="O2" value="59.2"/>
                    <measurement group_id="O3" value="54.2"/>
                    <measurement group_id="O4" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9"/>
                    <measurement group_id="O2" value="58.5"/>
                    <measurement group_id="O3" value="52.6"/>
                    <measurement group_id="O4" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="48.2"/>
                    <measurement group_id="O4" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="48.9"/>
                    <measurement group_id="O4" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Lens Awareness Individual Item</title>
        <description>Frequency of Lens Awareness was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are scaled as (Always, Frequently, Occasionally, Rarely, Never or Don't Know). Only the number of participants that reported Rarely or Never (Top-Two-Box) was reported here.</description>
        <time_frame>1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Lens Awareness Individual Item</title>
          <description>Frequency of Lens Awareness was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are scaled as (Always, Frequently, Occasionally, Rarely, Never or Don't Know). Only the number of participants that reported Rarely or Never (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="74.5"/>
                    <measurement group_id="O3" value="77.4"/>
                    <measurement group_id="O4" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                    <measurement group_id="O2" value="61.6"/>
                    <measurement group_id="O3" value="54.9"/>
                    <measurement group_id="O4" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="63.9"/>
                    <measurement group_id="O3" value="45.6"/>
                    <measurement group_id="O4" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="54.2"/>
                    <measurement group_id="O4" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="51.2"/>
                    <measurement group_id="O4" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Experiencing Dryness Individual Item</title>
        <description>Frequency of Experiencing Dryness was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are scaled as (Always, Frequently, Occasionally, Rarely, Never or Don't Know). Only the number of participants that reported Rarely or Never (Top-Two-Box) was reported here.</description>
        <time_frame>1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Experiencing Dryness Individual Item</title>
          <description>Frequency of Experiencing Dryness was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are scaled as (Always, Frequently, Occasionally, Rarely, Never or Don't Know). Only the number of participants that reported Rarely or Never (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7"/>
                    <measurement group_id="O2" value="67.7"/>
                    <measurement group_id="O3" value="71.4"/>
                    <measurement group_id="O4" value="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="53.4"/>
                    <measurement group_id="O4" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2"/>
                    <measurement group_id="O2" value="50.1"/>
                    <measurement group_id="O3" value="50.4"/>
                    <measurement group_id="O4" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="59.2"/>
                    <measurement group_id="O3" value="51.2"/>
                    <measurement group_id="O4" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="55.4"/>
                    <measurement group_id="O3" value="50.4"/>
                    <measurement group_id="O4" value="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Making Your Eyes Feel Moist Throughout the Day Individual Item</title>
        <description>Making your eyes feel moist throughout the day was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
        <time_frame>Up to 1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Making Your Eyes Feel Moist Throughout the Day Individual Item</title>
          <description>Making your eyes feel moist throughout the day was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                    <measurement group_id="O2" value="52.3"/>
                    <measurement group_id="O3" value="43.7"/>
                    <measurement group_id="O4" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="52.3"/>
                    <measurement group_id="O3" value="43.7"/>
                    <measurement group_id="O4" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                    <measurement group_id="O2" value="53.1"/>
                    <measurement group_id="O3" value="49.7"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="48.5"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="43.6"/>
                    <measurement group_id="O4" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Overall Quality of Vision Composite Score</title>
        <description>Subjective Overall Quality of Vision was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. CLUE was collect at Baseline, Post Lens Fit 1-, 2-, 3- and 4- week follow-ups.</description>
        <time_frame>Up to 1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Overall Quality of Vision Composite Score</title>
          <description>Subjective Overall Quality of Vision was evaluated using the Contact Lens User Experience Comfort scores (CLUE). CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. CLUE was collect at Baseline, Post Lens Fit 1-, 2-, 3- and 4- week follow-ups.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.79" spread="20.515"/>
                    <measurement group_id="O2" value="63.31" spread="20.510"/>
                    <measurement group_id="O3" value="64.12" spread="19.822"/>
                    <measurement group_id="O4" value="62.34" spread="19.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Fit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.45" spread="14.896"/>
                    <measurement group_id="O2" value="68.96" spread="16.272"/>
                    <measurement group_id="O3" value="65.58" spread="17.300"/>
                    <measurement group_id="O4" value="67.07" spread="16.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.32" spread="20.897"/>
                    <measurement group_id="O2" value="63.55" spread="20.586"/>
                    <measurement group_id="O3" value="59.36" spread="22.076"/>
                    <measurement group_id="O4" value="58.61" spread="19.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.77" spread="20.222"/>
                    <measurement group_id="O2" value="61.66" spread="20.504"/>
                    <measurement group_id="O3" value="58.29" spread="23.543"/>
                    <measurement group_id="O4" value="56.54" spread="21.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.22" spread="21.125"/>
                    <measurement group_id="O2" value="61.41" spread="22.137"/>
                    <measurement group_id="O3" value="57.27" spread="22.463"/>
                    <measurement group_id="O4" value="53.65" spread="22.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.30" spread="22.852"/>
                    <measurement group_id="O2" value="60.99" spread="22.573"/>
                    <measurement group_id="O3" value="56.63" spread="24.879"/>
                    <measurement group_id="O4" value="53.57" spread="23.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Quality of Vision Individual Item</title>
        <description>Overall Quality of Vision was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the number of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
        <time_frame>Up to 1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Quality of Vision Individual Item</title>
          <description>Overall Quality of Vision was assessed using a questionnaire item at Baseline, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the number of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="91.0"/>
                    <measurement group_id="O4" value="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="77.7"/>
                    <measurement group_id="O3" value="74.9"/>
                    <measurement group_id="O4" value="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="77.7"/>
                    <measurement group_id="O3" value="69.1"/>
                    <measurement group_id="O4" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6"/>
                    <measurement group_id="O2" value="76.9"/>
                    <measurement group_id="O3" value="69.9"/>
                    <measurement group_id="O4" value="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1"/>
                    <measurement group_id="O2" value="76.2"/>
                    <measurement group_id="O3" value="63.2"/>
                    <measurement group_id="O4" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Opinion Individual Item</title>
        <description>Overall Opinion was assessed using a questionnaire item at Post Fit, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
        <time_frame>Up to 1 month Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B</title>
            <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
          </group>
          <group group_id="O4">
            <title>Samfilcon A</title>
            <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Opinion Individual Item</title>
          <description>Overall Opinion was assessed using a questionnaire item at Post Fit, 1-week, 2-week, 3-week and 4-week follow-up. Reposes are on a 5 likert scale (Excellent, Very Good, Good, Fair and Poor). Only the percentage of participants that reported Excellent or Very good (Top-Two-Box) was reported here.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post Fit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="60.9"/>
                    <measurement group_id="O4" value="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                    <measurement group_id="O2" value="49.3"/>
                    <measurement group_id="O3" value="42.1"/>
                    <measurement group_id="O4" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="42.1"/>
                    <measurement group_id="O4" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4- Week Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="38.3"/>
                    <measurement group_id="O4" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the duration of the study. Approximately 1 month per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon C</title>
          <description>Subjects that were randomized to receive the senofilcon C lens throughout the duration of the study.</description>
        </group>
        <group group_id="E2">
          <title>Comfilcon A</title>
          <description>Subjects that were randomized to receive the comfilcon A lens throughout the duration of the study.</description>
        </group>
        <group group_id="E3">
          <title>Lotrafilcon B</title>
          <description>Subjects that were randomized to receive the lotrafilcon B lens throughout the duration of the study.</description>
        </group>
        <group group_id="E4">
          <title>Samfilcon A</title>
          <description>Subjects that were randomized to receive the samfilcon A lens throughout the duration of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasm in Chest</sub_title>
                <description>Not related to the study article.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristy Canavan, O.D. PRINCIPAL RESEARCH OPTOMETRIST</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>904-443-1474</phone>
      <email>KCANAVA2@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

